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Multicolumn spinal cord stimulation for
predominant back pain in failed back surgery
syndrome patients: a multicenter randomized
controlled trial
Philippe Rigoarda,b,c,*, Surajit Basud, Mehul Desaie,f, Rod Taylorg, Lieven Annemansh, Ye Tani, Mary Jo Johnsoni,
Carine Van den Abeelej, PROMISE Study Group, Richard Northk,l
Abstract
Despite optimal medical management (OMM), low back pain (LBP) can be disabling, particularly after spinal surgery. Spinal cord
stimulation (SCS) is effective in reducing neuropathic leg pain; however, evidence is limited for LBP. This prospective, open-label, parallel-
group trial randomized (1:1) failed back surgery syndrome (FBSS) patientswith predominant LBP toSCSplusOMM (SCSgroup) orOMM
alone (OMMgroup) at 28 sites in Europe and the Americas. If trial stimulationwas successful, amulticolumnSCS systemwas implanted.
Outcomes were assessed at baseline (before randomization) and at 1, 3, 6, and 12 months after randomization. Patients could change
treatment groupsat 6months. Theprimaryoutcomewas theproportion of patientswith$50%reduction in LBP (responder) at 6months.
Secondary outcomes included change in pain intensity, functional disability, and health-related quality of life (HRQoL). The results are
posted at ClinicalTrials.gov under registration number NCT01697358. In the intent-to-treat analysis, there were more responders in the
SCSgroup than in theOMMgroup (13.6%, 15/110 vs4.6%, 5/108, difference9%with 95%confidence interval 0.6%-17.5%,P50.036)
at 6 months. The SCS group improved in all secondary outcomes compared with the OMM group. The OMM group only improved in
HRQoL. In the SCS group, 17.6% (18/102) experienced SCS-related adverse events through 6 months, with 11.8% (12/102) requiring
surgical reintervention. Adding multicolumn SCS to OMM improved pain relief, HRQoL, and function in a traditionally difficult-to-treat
population of failed back surgery syndrome patients with predominant LBP. Improvements were sustained at 12 and 24 months.
Keywords:Spinal cord stimulation, Surgical leads, Failed back surgery syndrome, Randomized controlled trial, Chronic low back
pain, Predominant back pain
1. Introduction
Spinal pathologies and low back pain (LBP) represent a major
public health issue and impose a considerable financial burden
on the society.2 Low back pain affects 60% to 80% of the
population at some point in life,13,15 and pharmacological
treatments can be suboptimal.4,11
A substantial fraction of patients who undergo spinal surgery
develop new or persistent back and/or leg pain postopera-
tively.4,19,20,23 This chronic condition is described as failed back
surgery syndrome (FBSS) or postlaminectomy syndrome and
remains difficult to treat with conventional medical management
alone.8
Spinal cord stimulation (SCS) for pain control has been
available for 50 years. It is delivered through electrodes placed
in the dorsal epidural space to produce paresthesia in the painful
area. Several systematic reviews of the impact of SCS in chronic
back and leg pain and FBSS have been published.16,31–33 The
systematic review by Taylor et al. in 2014 identified 74 included
SCS studies (in 3025 patients) of which only 4 studies (in 104
patients) were in the population with predominant LBP; the
remainder were in predominant leg pain (9 studies), mixed back
and leg pain (22 studies), or unclassifiable (39 studies). There was
evidence of a higher level of pain relief pooled across studies in
individuals with predominant back pain after SCS (mean 86%
pain relief, 95% confidence interval [CI]: 75%-96%) compared
with studies in those with predominant leg pain (mean 53% pain
relief, 95% CI: 39%-68%), but the number of studies analyzed
was small, and there was no significant association (P 5 0.49)
between the level of pain relief and the location of pain in
univariable meta-regression. Furthermore, these 4 studies in
predominant LBP were all case series and therefore low in the
hierarchy of evidence. The authors recommended randomized
controlled trials (RCTs) to confirm the effectiveness and cost-
effectiveness of SCS in the population with predominant LBP that
included important measurements beyond pain relief including
level of physical disability and health-related quality of life
(HRQoL). Although SCS is an established and effective treatment
in FBSS for predominant radicular pain,18,24,31 LBP has been
difficult to treat with traditional SCS. Initial reports on the use of
SCS with a multicolumn lead (electrode array) have shown
promising results.27
PROMISE was designed to address this gap in LBP evidence.
It is an international RCT of SCS in a population of exclusively
predominant LBP FBSS patients to compare the clinical
effectiveness of SCS with a multicolumn lead combined with
optimal medical management (OMM) to OMM alone.
2. Methods
The PROMISE trial was conducted and reported in accordance
with the Consolidated Standards of Reporting Trials guidelines.22
The study design, previously published,28 is summarized below.
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2.1. Study design
PROMISE was a multicentre, prospective, randomized, open-
label, parallel-group, controlled trial conducted at 28 investiga-
tional sites in Belgium, Canada, Colombia, France, Germany, the
Netherlands, Spain, the United Kingdom, and the United States.
The study was conducted in accordance with ISO 14155, and
ethics committee/institutional review board approval was
obtained at each site. Surgeons at each site were required to
have experience implanting a minimum of 6 multicolumn surgical
leads before study participation.
2.2. Patients
Failed back surgery syndrome patients, identified through
standard clinical practice at each site (eg, call logs, chart reviews,
scheduled visits, and referrals), were evaluated systematically for
study eligibility and provided consent before enrollment. Study
patients had an FBSS diagnosis, no indication for further spine
surgery, an average LBP score of $5 on the 7-day pain diary
completed twice daily (morning and evening) at home using the
Numeric Pain Rating Scale (NPRS), an average leg pain less than
their mean back pain, and were candidates for SCS using the
studied surgical lead.
The initial pain diary was completed after enrollment within 2
weeks before the randomization visit. Patients were not informed
of the success criteria, and those who did not meet the pain
inclusion criteria were discontinued from the study.
2.3. Randomisation and masking
Patients were randomly allocated (1:1 ratio) to SCS1OMM (SCS
group) or OMM alone (OMM group) using random, permuted
blocks of 4 and 2 stratified by investigational site. To maintain
allocation concealment, randomization assignments were pro-
vided using an electronic data management system. Due to the
nature of the treatments, the treating physicians and patients
could not be blinded to the treatment group.
2.4. Procedures
Given the lack of international guidance, an OMM guideline was
developed by the PROMISE Trial Steering Committee (TSC) to
standardize practice in the study. An individual OMM treatment plan
was developed for each patient and optimized at each visit. Optimal
medical management could include treatments ranging from
noninvasive treatments such as acupuncture, psychological/
behavioural therapy, and physiotherapy to invasive treatments such
as spinal injections/blocks, epidural adhesiolysis, and neurotomies.
Patients randomized to SCS underwent trial stimulation with
a surgical lead or percutaneous leads, based on the standard
practices used at the site. Trial success was defined as a subject
having adequate LBP relief with usual activity and appropriate
analgesia in the context of postoperative pain (thoracic laminec-
tomy in particular, when applicable), as assessed by the
investigator. If the trial was successful, a permanent SCS system
was implanted using the multicolumn surgical lead (Specify 5-6-
5; Medtronic) and neurostimulator (Models 37701, 37702,
37712, 37713, 37714, 97702, 97713, and 97714; Medtronic),
according to usual practice at the site. Outcomes were assessed
at baseline (before randomization) and at 1, 3, 6, 12, and 24
months after randomisation. After 6 months, patients could
change treatment groups.
2.5. Outcomes
The primary analysis was the proportion of responders in each
group. The primary outcomewas success or failure, and success
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was defined as $50% reduction in LBP. Secondary outcomes
were back and leg pain intensity (NPRS), disability (Oswestry
Disability Index [ODI]10), and HRQoL (Short Form-36 [SF-36]
Physical Component Score [PCS]35).
Additional outcome measures included the $30% LBP re-
sponder rate, 2-point LBP responder rate, SF-36 Mental Compo-
nent Score, EuroQoL-5D (EQ-5D-5L),12 sleep (Pittsburgh Sleep
Quality Index),3 Patient Global Impression of Change (PGIC),14
employment status, pain treatments, and patient satisfaction.
Adverse events (AEs) were reported and coded according to the
Medical Dictionary for Regulatory Activities (MedDRA), version 19.1.
An independent clinical events committee adjudicated AEs.
There were 3 analysis sets: intent-to-treat (ITT), completers,
and as-treated. The ITT analysis consisted of all patients
according to the randomization allocation. Completers analysis
consisted of patients according to the randomization allocation
who contributed complete data sets. As-treated analysis con-
sisted of patients’ actual treatment at the analysis timepoint and
complete data sets.
2.6. Statistical analysis
Theprimary hypothesiswas that theproportionof LBP responders in
the SCS group would be greater than that in the OMM group. A
minimum sample of 212 was required to provide 90% power to
detect a between-group difference of 20% in responder rates. The
assumptions of between-group difference were based on results of
the PROCESS RCT.18 Sample size reestimation was conducted by
an independent statistician when 140 patients reached 6 months of
follow-up using Lan-DeMets with O’Brien-Fleming boundary
methods. No adjustments to sample size resulted from this analysis.
For the primary and secondary objectives at 6months, the primary
analysis followed the ITT principle. In addition, completers and as-
treated analyses were undertaken. The following analysis definitions
were applied: ITT, between-group comparison based on random
allocation of all patients; completers, between-group comparison
based on random allocation of patients with complete data; and as-
treated, between-group analysis based on the treatment received at
6 months and on patients with complete data. Patients with missing
datawere treatedasnonresponders for theprimaryobjectiveandno-
change for secondary objectives for the ITT analysis. For additional
outcome measures, the as-treated populations were used.
Responder rates were compared by a Z-test using an unpooled
SD with continuity correction between the SCS and OMM groups.
Linear regression models were used to assess secondary out-
comes, comparing the baseline to follow-up score changes
between the SCS andOMMgroups, adjusting for baseline outcome
scores. A treatment-by-site interaction term was tested in each
model. If the interaction term approached significance (defined as
,0.10), that term remained in the final model with the term for site. In
addition, within-group comparisons to baseline were performed
using a paired t test or a Wilcoxon signed rank test.
Given the extent of patient cross-over to SCS after 6 months, 12-
month and 24-month analyses were limited to a within-group
comparison in the SCS group using either a paired t test or
a Wilcoxon signed rank test. In an exploratory post hoc analysis
using univariate and multivariate logistic regression, demographic
factors of age, sex, bodymass index (BMI), region, durationof FBSS,
number and type of prior spinal surgeries (fusion vs nonfusion), type
of pain, and worker’s compensation were analyzed.
A P-value of ,0.05 was considered statistically significant. To
maintain an overall type I error rate at 0.05, a fixed-sequence
method for the multiplicity adjustment of hierarchical endpoints
was used for the primary and secondary objectives. Analyses
were prespecified in a detailed statistical analysis plan and
performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC). A
data monitoring committee was not used for this study, given that
the TSC was providing oversight.
The study is posted at Clinicaltrials.gov under registration
number NCT01697358.
2.7. Role of the funding source
Medtronic funded the study andwas involved in the study design,
data collection, data analysis, data interpretation, and writing of
the report. The corresponding author had access to all the data in
the study and had final responsibility for the decision to submit for
publication.
3. Results
3.1. Study population
Patients were screened from January 8, 2013, through August 31,
2015, with the last patient enrolled on August 15, 2015, and the final
patient visit on June 20, 2017. Of the 2858 FBSS patients screened,
1199were considered as potential candidates, 548 (46%) opted not
to participate, and 373 (31%) were excluded due to SCS and/or
study contraindication(s). A total of 278 patients were enrolled, of
which 218 were randomized, 110 to SCS with OMM and 108 to
OMM alone. Patient disposition is provided in Figure 1.
Baseline characteristics and outcomes did not differ between
groups (Table 1). Overall, randomized patients experienced
FBSS symptoms for 6.7 years on average. Previous surgeries
were 68.5% fusion (fusion or disk replacement) and 31.2%
nonfusion (discectomy, laminectomy, laminotomy, foramenec-
tomy, foraminotomy, and other). The majority had more than
one surgery and were unable to work. Mean pain was
predominant in the back (7.5/10) and moderate (5.3/10) in the
leg(s). Pain seemed to be neuropathic in 84.4% of cases as
indicated by the Neuropathic Pain questionnaire, Douleur
Neuropathique 4 [DN4]1. Most patients reported severe
disability (mean ODI: 54.9) and low HRQoL (mean EQ-5D-5L
index: 0.35). Mean BMI was 29.8 kg/m2.
3.2. Temporary trial period
In the SCS group, 69.6% (71/102) of patients were trialed with the
multicolumn surgical lead and 30.4% (31/102) with percutaneous
leads. Of the 102 patients trialed, 82 (80.3%) continued to
permanent system implant, with 52.4% (43/82) receiving a re-
chargeable system and 47.6% (39/82) a nonrechargeable
system.
3.3. Permanent system
All patients received the multicolumn surgical lead and a com-
patible neurostimulator (model 97714, n 5 49; 37702, n 5 39;
97702, n 5 27; 37714, n 5 12; 97712, n 5 4; 37713, n 5 3;
97713, n 5 3; 37712, n 5 2; and 37701, n 5 1). Eighty-two
neurostimulators were implanted in the SCS1OMMpatients and
58 neurostimulation systems were implanted in the OMM
patients, 1 before the 6-month visit and the others after the
6-month visit.
3.4. Primary outcome at 6 months
In the ITT analysis, 15 SCS patients (13.6%) and 5 OMM patients
(4.6%) achieved$50% LBP relief (risk difference 9%with 95%CI
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0.6%-17.5%, P 5 0.036, Table 2). The primary objective was
met. The SCS group responder rate ranged from 0% to 50%
across sites.
In the completers analysis, the LBP responder rate in the SCS
groupwas 16.3% and it was 4.8% (P5 0.017) in the OMMgroup.
In the as-treated analysis, the LBP pain responder rate in the SCS
group was 20.3% and it was 3.4% (P5 0.001) in the OMM group
(Table 2).
The proportion of the as-treated SCS group reporting
a clinically meaningful reduction in LBP of $30% was 39.2%
compared with 12.0% in the OMM group. The proportion of SCS
group patients with a$2-point LBP NPRS reduction was 43.0%
Figure 1. CONSORT diagram of patient flow. OMM, optimal medical management; SCS, spinal cord stimulation.
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compared with 11.1% in OMM patients. (Table S1, available at
http://links.lww.com/PAIN/A751).
The post hoc exploratory regression analysis identified that
BMI and treatment allocation were the only predictors of the
primary outcome for both groups.
3.5. Secondary outcomes at 6 months
Secondary endpoint ITT, completers, and as-treated analyses
are reported in Table 3.
In the as-treated analysis, mean back and leg pain intensity in
the SCS group were reduced 2.0 points, from 7.5 to 5.4 (P ,
0.001), and 1.6 points, from 5.2 to 3.7 (P , 0.001), respectively,
and were unchanged in the OMM group (Table 3 and Figs. 2
and 3). The leg pain responder rate in the SCS group was 40.5%
and 8.5% in the OMM group (Table S1, available at http://
links.lww.com/PAIN/A751). Mean ODI score decreased from
55.9 to 43.9 in the SCS group (P, 0.001) and was unchanged in
the OMM group (from 54.4 to 53.2) (Table 3). The proportion of
patients in the “crippled”/“bedbound” categories was reduced
from 40.5% to 13.9% in the SCS group and from 33.4% to 28.2%
in the OMM group (Fig. 4). For HRQoL, mean SF-36 PCS scores
improved from 24.08 to 31.58 (P, 0.001) in the SCS group and
were unchanged in the OMM group (Table 3).
3.6. Additional results at 6 months
Additional outcomes were evaluated at 6 months using the as-
treated data set. All, except work status and SF-36 Mental
Component Score, improved in the SCS group and were
unchanged in the OMM group. (Table S2, available at http://
links.lww.com/PAIN/A751). In the SCS group, mean EQ-5D-5L
index value increased from 0.31 to 0.49, and the Pittsburgh Sleep
Quality Index improved from 13.1 to 10.8. A significant favorable
PGIC improvement (“moderately,” “better,” or “a great deal
better”) was reported in 59.0% of SCS group patients compared
with 10.3% in the OMM group. Satisfaction was high with 82.1%
of SCS patients stating they were “somewhat” or “very satisfied”
with the therapy, compared to 53.9% in the OMM group.
The number of OMM treatments received differed between the 2
treatment groups; 3.8% (3/79) of SCS subjects used a total of 3
invasive treatments between baseline and 6months compared with
24.8% (29/117) of OMM subjects who used a total of 69 invasive
treatments. For noninvasive treatments, 30.4% (24/79) of SCS
subjects used a total of 431 noninvasive treatments compared with
Table 1
Baseline demographics.
Variable Total randomized SCS 1 OMM OMM
N 5 218 n 5 110 n 5 108
Age at consent (y): Mean (SD) 53.9 (11.5) 52.8 (12.5) 55.1 (10.2)
Sex: Female, n (%) 132 (60.6%) 68 (61.8%) 64 (59.3%)
Body mass index (BMI): Mean (SD) 29.8 (5.4) 30.0 (5.1) 29.7 (5.7)
Etiology of pain that led to original surgery, n (%)
Herniated disk 109 (50.0%) 57 (51.8%) 52 (48.2%)
Other (combinations) 66 (30.3%) 33 (30.0%) 33 (30.6%)
Spondylolisthesis 17 (7.8%) 9 (8.2%) 8 (7.4%)
Unknown 17 (7.8%) 9 (8.2%) 8 (7.4%)
Spinal deformity 6 (2.8%) 2 (1.8%) 4 (3.7%)
Fracture 3 (1.4%) 0 (0%) 3 (2.8%)
Years since FBSS symptoms onset: Mean (SD) 6.7 (7.2) 6.4 (7.4) 7.0 (7.1)
Years since last surgery*: Mean (SD) 5.4 (5.9) 5.3 (6.2) 5.6 (5.5)
No. of previous spinal surgeries*: Mean (SD) 2.0 (1.2) 1.9 (1.2) 2.0 (1.3)
Unable to work, n (%) 111 (50.9%) 64 (58.2%) 47 (43.5%)
Neuropathic pain (DN4 $4), n (%) 184 (84.4%) 94 (85.5%) 90 (83.3%)
Low back pain NPRS: Mean (SD) 7.5 (1.2) 7.5 (1.2) 7.6 (1.2)
Leg pain NPRS: Mean (SD) 5.3 (2.0) 5.4 (1.9) 5.3 (2.1)
EQ-5D-5L index value 0.35 (0.26) 0.34 (0.27) 0.36 (0.24)
ODI: Mean (SD) 54.9 (14.4) 55.0 (14.6) 54.8 (14.4)
* All patients had at least one previous spinal surgery, either fusion (fusion or disk replacement) or nonfusion (discectomy, laminectomy, laminotomy, foramenectomy, foraminotomy, or other).
FBSS, failed back surgery syndrome; NPRS, Numeric Pain Rating Scale; ODI, Oswestry Disability Index; OMM, optimal medical management; SCS, spinal cord stimulation.
Table 2
Primary outcome: LBP responders at 6 months.
Analysis SCS 1 OMM responders OMM responders Between-group risk difference (95% CI) Between-group difference, P
# n % # n %
ITT 15 110 13.6 5 108 4.6 9% (0.6%-17.5%) 0.036
Completers 15 92 16.3 5 104 4.8 11.5% (1.9%-21.1%) 0.017
As-treated 16 79 20.3 4 117 3.4 16.8% (6.3%-27.3%) 0.001
CI, confidence interval; ITT, intent-to-treat; LBP, low back pain; OMM, optimal medical management; SCS, spinal cord stimulation.
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47.9% (56/117) of OMM subjects who used a total of 1622
treatments. Scheduled study visits were at 1, 3, 6, 12, and 24
months after randomization. Outside these regularly scheduled
visits, 60.8% (48/79) of SCS subjects in the as-treated analysis had
a total of 401 nontreatment consultations comparedwith 49.6% (58/
117) of OMM subjects who had a total of 246 consultations (Table
S3, Fig. S1, available at http://links.lww.com/PAIN/A751).
When taking all 3 types of contacts (invasive, noninvasive, and
nontreatment consultations) into consideration, the OMM sub-
jects had more than twice as many interactions with a health care
provider as the SCS subjects.
The proportion of patients taking pain medication decreased or
remained unchanged in the SCS group and increased in the OMM
group, except for anxiolytics, which increased in both groups. In the
SCS group, pain medication changes were associated with “pain
level improvement” in 46.8% of patients compared to 17.9% in the
OMMgroup.Medication changes due to “side effects”were higher in
theOMMgroup (20.5%) than in theSCSgroup (2.5%) (TablesS4and
S5, available at http://links.lww.com/PAIN/A751). Mean baseline
morphinemilligram equivalents (MME) dosage in the SCS group was
59.5and57.5 in theOMMgroup.At6months, therewasastatistically
significant difference in MMEbetween groups (P5 0.031) withmean
MME unchanged (58.5) in the SCS group and increased (64.8) in the
OMMgroup. (TableS2, available at http://links.lww.com/PAIN/A751).
Spinal cord stimulation programming information is provided in
Tables S6 and S7 and Fig. S2, available at http://links.lww.com/
PAIN/A751.
At 6 months, 2.4% (2/83) of SCS-implanted patients opted to
cease SCS therapy, whereas 72.6% (77/106) of OMM patients
requested to crossover to SCS (Table S8, available at http://
links.lww.com/PAIN/A751).
3.7. Twelve-month outcomes
Analysis was performed on patients reaching 12 months, those
continuing SCS from Period I (SCS-SCS) and OMM subjects
moving to SCS in Period II (OMM-SCS). Of the 61.8% (68/110)
continuing SCS and reporting 12-month data, 26.5% (18/68)
achieved $50% reduction in LBP (Table S9, Fig. S3, available at
http://links.lww.com/PAIN/A751). Mean (SD) LBP improvement
in patients continuing SCS at 12 months was 2.3 (2.2) points. In
SCS-SCS patients with baseline and 12-month data (n 5 66),
mean (SD) improvements were seen in ODI 10.7 (18.6), EQ-5D-
5L 0.17 (0.30), and SF-36 PCS 6.92 (8.30), all with P , 0.001.
3.8. Twenty-four-month outcomes
Of the 57.3% (63/110) continuing SCS (SCS-SCS) and reporting
24-month data, 20.6% (13/63) achieved$50% reduction in LBP
(Table S9, Fig. S3, available at http://links.lww.com/PAIN/A751).
Mean (SD) LBP improvement was 2.2 (2.0) points. Mean (SD)
improvements were seen inODI 9.4 (15.2), EQ-5D-5L 0.18 (0.29),
and SF-36 PCS 6.45 (8.71), all with P , 0.001.
3.9. Adverse events
In the SCS group, 17.6% (18/102) of trialed patients experienced
SCS-related AEs during the period from randomization through 6
months (Table 4). Among these, 11.8% (12/102) required
surgical intervention to treat the event. The most frequent SCS-
related AE was implant site infection (6.9%), in which 7 patients
experienced 8 implant site infection events. Infections were
associated with longer temporary trial duration and resulted in
a protocol change to limit trial duration to 10 days or fewer.
Among all trialed patients regardless of randomization assign-
ment, the SCS-related AE analysis at 24 months concluded that
the overall infection rate was 5% (9/174), after combining
infections that occurred within 90 days of initial lead implant
(implant site infection, extradural abscess, and implant cellulitis)
(Table S10, available at http://links.lww.com/PAIN/A751). The
patient with extradural abscess also experienced hematoma and
monoparesis, which resolved with sequela of paresis at the time
of study exit after lead explant. The most frequent non–SCS-
related AEs were falls and adverse drug reactions (Table S11,
available at http://links.lww.com/PAIN/A751).
4. Discussion
The PROMISE study shows that the addition of SCS to OMM for
patients with FBSS with predominant LBP was superior on back
Table 3
Secondary outcomes: NPRS, ODI, and HRQoL at 6 months.
Secondary outcomes SCS 1 OMM OMM Between-group
difference, (95% CI)
Between
group, PBaseline 6-mo Change
from
baseline
Within
group, P
Baseline 6-mo Change
from
baseline
Within
group, P
Low back pain NPRS mean (SD)
ITT 7.5 (1.2) 6.0 (2.1) 1.4 (1.9) ,0.001 7.6 (1.2) 7.2 (1.9) 0.3 (1.7) 0.399 1.1 (0.6-1.6) ,0.001
Completers 7.5 (1.2) 5.8 (2.1) 1.7 (2.0) ,0.001 7.6 (1.2) 7.2 (1.9) 0.4 (1.7) 0.399 1.3 (0.8-1.9) ,0.001
As-treated 7.5 (1.2) 5.4 (2.1) 2.0 (1.9) ,0.001 7.5 (1.2) 7.3 (1.8) 0.3 (1.6) 0.507 1.7 (1.2-2.2) ,0.001
Leg pain NPRS mean (SD)
ITT 5.4 (1.9) 4.2 (2.4) 1.2 (2.1) ,0.001 5.3 (2.1) 5.4 (2.4) 20.1 (2.4) 0.437 1.3 (0.7-1.9) ,0.001
Completers 5.3 (1.8) 3.9 (2.4) 1.4 (2.2) ,0.001 5.2 (2.1) 5.3 (2.5) 20.1 (2.4) 0.437 1.5 (0.9-2.2) ,0.001
As-treated 5.2 (1.9) 3.7 (2.4) 1.6 (2.3) ,0.001 5.3 (2.0) 5.4 (2.4) 20.0 (2.3) 0.684 1.6 (0.9-2.3) ,0.001
ODI mean (SD)
ITT 55.0 (14.6) 46.9 (17.9) 8.1 (14.7) ,0.001 54.8 (14.4) 53.1 (17.1) 1.8 (14.3) 0.093 6.3 (2.5-10.2) ,0.001
Completers 55.0 (14.2) 45.3 (17.7) 9.7 (15.6) ,0.001 55.0 (14.3) 53.2 (17.1) 1.8 (14.6) 0.093 7.9 (3.6-12.1) ,0.001
As-treated 55.9 (14.6) 43.9 (18.4) 12.0 (16.1) ,0.001 54.4 (14.0) 53.2 (16.4) 1.1 (13.5) 0.192 10.9 (6.7-15.1) ,0.001
HRQoL, SF-36 PCS mean (SD)
ITT 24.55 (7.13) 29.82 (9.78) 5.27 (8.28) ,0.001 24.72 (6.70) 26.06 (6.59) 1.34 (6.28) 0.028 3.9 (2.0-5.9) ,0.001
Completers 24.06 (6.80) 30.35 (9.98) 6.30 (8.69) ,0.001 24.61 (6.78) 26.00 (6.67) 1.39 (6.39) 0.028 4.9 (2.8-7.0) ,0.001
As-treated 24.08 (6.73) 31.58 (10.04) 7.50 (8.72) ,0.001 24.53 (6.83) 25.66 (6.60) 1.12 (6.17) 0.071 6.4 (4.3-8.5) ,0.001
CI, confidence interval; HRQoL, health-related quality of life; ITT, intent-to-treat; NPRS, Numeric Pain Rating Scale; ODI, Oswestry Disability Index; OMM, optimal medical management; PCS, Physical Component Score; SCS,
spinal cord stimulation.
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and leg pain, HRQoL, function, PGIC, and satisfaction compared
to OMM alone. These improvements observed at 6 months with
SCS were sustained at 12 and 24 months. The safety profile of
SCS is in linewith the literature. Despitemore patients in theOMM
group using invasive/semiinterventional treatments (24.8% of
OMM subjects compared with 3.8% of SCS subjects), non-
invasive treatments (47.9% compared with 30.4%), and in-
creasing medications during the 6-month comparative phase,
the OMMgroup did not show a statistically or clinically meaningful
change in back or leg pain NPRS or function. The SCS group,
however, showed both a statistically and clinically meaningful
reduction in pain and improvement in function in this difficult-to-
treat population, with stable/reduced medication intake.
In this multicenter study, the magnitude of reduction in pain and
50% response is lower than that reported in studies with the same
lead,26,27,29 other leads,25 or alternative frequencies of SCS
stimulation.17 In studies with the same lead, an observational
single-center study of 11 carefully selected FBSSpatients reported
amean VASbackpain score decrease from7.8baseline to 1.5 at 6
months.27 A prospective, three-center study of 76 consecutive
patients reported that 42.1% of patients obtained at least 50%
improvement of the back pain VAS score.29 A larger single-center
prospective observational study of 62 patients reportedmean VAS
change from 9 preoperatively to 5 at 36 months.26 We believe that
the modest pain effects with SCS seen in the study may reflect the
difficult-to-treat population in this trial.
Although recent RCTs reaffirmed the benefits of SCS, in
contrast to PROMISE, they did not specifically enroll patients with
predominant LBP FBSS.7,17 The Senza study enrolled subjects
with back pain and leg pain$5.17 The SUNBURST study enrolled
patients with amix of chronic trunk and/or limb pain with inclusion
criteria of VAS pain scores $60.30
Moreover, the PROMISE patient population is more function-
ally impaired than in other studies. First, 36% of patients rated
themselves as “crippled” compared with 20% in the SENZA
study. Second, patients came into the study with a long history of
back pain, functional disability, and poor HRQoL. Third, their
average BMI was 29.8 kg/m2 (ie, borderline obese), which was
Figure 2. Low back pain intensity, as-treated. OMM, optimal medical management; SCS, spinal cord stimulation.
Figure 3. Leg pain intensity, as-treated. OMM, optimal medical management; SCS, spinal cord stimulation.
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shown to be a statistically significant prognostic factor for the
primary outcome (higher BMI correlated with a lower level of
response to SCS and OMM).
It is important to note that despite relatively small improvement
in pain relief, the gains in HRQoL, function, and patient
satisfaction with SCS reported by patients in this study are
comparable with the those reported in the literature.7,17,18,24,25
The disproportionately better improvements in function, HRQoL,
PGIC, and satisfaction compared with pain reduction point not
only to the importance of using HRQoL and function in assessing
Figure 4. Oswestry Disability Index, as-treated. ODI, Oswestry Disability Index; OMM, optimal medical management; SCS, spinal cord stimulation.
Table 4
Spinal cord stimulation–related adverse events, randomization to 6-month visit.
CECa-adjudicated etiology MedDRA
preferred term
No. of
serious events
No. of events No. of patients
with events
Proportion of patients
with event (n 5 102b)
No. of patients
with surgical intervention
Device Device stimulation issue 2 2 2 2.0% 2
Paresthesia 0 2 2 2.0% 2
Human Factors Device deployment issue 0 2 2 2.0% 2
Device battery issue 0 1 1 1.0% 1
Programming/stimulation Back pain 1 1 1 1.0% 0
Surgery/anesthesia Implant site infection 7 8 7 6.9% 5
Implant site cellulitis 0 1 1 1.0% 0
Implant site pain 1 1 1 1.0% 1
Pelvic pain 0 1 1 1.0% 0
Pulmonary oedema 1 1 1 1.0% 0
Urinary tract infection 1 1 1 1.0% 0
Total 13 21 18 17.6% 12
a CEC, Clinical Events Committee.
b Denominator (n 5 102) is the number of patients who underwent a screening test.
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therapy benefits6 in a population suffering from chronic LBP, but
also to the potential limitations of standard pain measures in this
population.5 Chronic LBP may have a mechanical component
that is more susceptible to fluctuation based on activity.34
This trial has several strengths. First, patients were systemat-
ically selected and enrolled consecutively at trial centers across
multiple geographies, which increases the generalizability of the
study results. Second, sites were asked to develop an individual
patient OMM treatment plan for all patients and review it at each
patient visit to ensure OMM was optimized and the comparator
was meaningful. The TSC authored OMM guidance for the study
investigators based on an understanding of the current literature
to define the OMM comparator as precisely and extensively as
possible.7 Third, outcomes were selected based on those
endorsed by the Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT)9 and International
Consortium for Health Outcomes Measurement.6 The primary
outcome was based on a 7-day, twice-daily paper pain diary and
questionnaires that were completed by patients using a secure
electronic tablet to reduce assessor bias. The use of pain intensity
as the primary outcome in trials of chronic back pain has recently
been criticized, and it has been recommended instead that
studies should focus on the domains of physical functioning and
HRQoL.9,34 The results of this trial support the assertion that the
traditional metric of$50% pain relief alone may fail to capture the
value of improvements in disability and HRQoL. By incorporating
secondary and additional outcomes, the PROMISE study was
able to comprehensively evaluate therapy benefits.
This study has some limitations. Studies of “conventional” SCS
are challenging to conduct in a double-blind fashion due to the
implant procedure, the patient programmer, and the perceptible
paresthesia experienced by subjects. The lack of blinding makes
assessments susceptible to assessment bias and placebo and
nocebo effects. The study used “conventional” SCS frequencies
and waveforms. Although preoperative imaging (to define the
level of the conus medullaris and guide lead implantation),
intraoperative paresthesia mapping (to guide electrophysiological
midline placement in awake patients), postoperative x-ray (to
document lead position), postoperative algorithmic program-
ming, and quantitative documentation of paresthesia coverage
were all encouraged, the application of those was left to the
discretion of the implanter and the center, and they were
implemented and documented variably and pragmatically.
Because the protocol did not include collection of imaging data
and the study did not standardize implantation and programming
practices across sites, it was not possible to determine whether
lead placement and programming were optimized at some
sites. This could, at least partially, explain the substantial
variability of SCS responders across the sites, and these
practices should be considered for further optimization of the
therapy. The study population had a high BMI, which may
compromise technically satisfactory SCS electrode placement
not only because the surgical exposure is deeper, but also
because it is more difficult to position a patient safely and
comfortably under awake anesthesia in a prone position for
paresthesia mapping.
The results of this study support the fact that multicolumn SCS
may be considered for FBSS patients suffering from chronic
predominant LBP. In recent years, alternative waveforms and
delivery of higher energy21,34 have emerged and show promising
outcomes. Future studies are needed to explore methods for
optimizing intraspinal neuroanatomical targeting (which techni-
cally rely on lead design, implantation parameters, and lead
programming) and the use of these alternative waveforms/higher
energy options (which depend on the pulse generator) as 2
complementary methods to increase SCS efficacy.
In conclusion, in this international multicenter RCT, adding
SCS with a multicolumn lead to OMM provided statistically
significant improvements in pain relief, HRQoL, and function
comparedwithOMMalone in a traditionally difficult-to-treat FBSS
patient population with predominant LBP. These improvements
were sustained in the SCS group at 12 and 24 months.
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